Merck (MRK) EPS (Basic) (2009 - 2026)

Merck has disclosed EPS (Basic) across 17 years of filings, most recently posting -$2.35 for Q1 2026.

• In Q1 2026, EPS (Basic) fell 182.77% year-over-year to -$2.35; the TTM figure through Mar 2026 stood at $5.02 (down 48.61% YoY), while the FY2025 annual figure was $10.21, up 6.6% from the prior year.
• EPS (Basic) slipped to -$2.35 in Q1 2026, from $1.66 in the prior quarter.
• Over the last five years, EPS (Basic) for MRK reached as high as $3.24 in Q3 2025 and fell as low as -$3.32 in Q2 2023.
• The 4-year median for EPS (Basic) is $2.09 (2024), against an average of $1.36.
• Annual changes were most pronounced in 2024 — EPS (Basic) jumped 405.38% — and 2026, when it slumped 182.77%.
• A 4-year view of EPS (Basic) shows it stood at -$0.69 in 2023, then soared by 405.38% to $2.09 in 2024, then retreated by 20.89% to $1.66 in 2025, then slumped by 242.1% to -$2.35 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$2.35, $1.66, and $3.24 for Q1 2026, Q4 2025, and Q3 2025 respectively.